205 related articles for article (PubMed ID: 28969629)
21. Clinician perspectives on clinical decision support systems in lung cancer: Implications for shared decision-making.
Ankolekar A; van der Heijden B; Dekker A; Roumen C; De Ruysscher D; Reymen B; Berlanga A; Oberije C; Fijten R
Health Expect; 2022 Aug; 25(4):1342-1351. PubMed ID: 35535474
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.
Wu SY; Lazar AA; Gubens MA; Blakely CM; Gottschalk AR; Jablons DM; Jahan TM; Wang VEH; Dunbar TL; Wong ML; Chan JW; Guthrie W; Belkora J; Yom SS
JAMA Netw Open; 2020 Sep; 3(9):e209750. PubMed ID: 32997124
[TBL] [Abstract][Full Text] [Related]
23. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
24. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
[TBL] [Abstract][Full Text] [Related]
25. Survival predictors in advanced non-small cell lung cancer.
Hespanhol V; Queiroga H; Magalhães A; Santos AR; Coelho M; Marques A
Lung Cancer; 1995 Dec; 13(3):253-67. PubMed ID: 8719065
[TBL] [Abstract][Full Text] [Related]
26. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
27. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
28. Exploring Stage I non-small-cell lung cancer: development of a prognostic model predicting 5-year survival after surgical resection†.
Guerrera F; Errico L; Evangelista A; Filosso PL; Ruffini E; Lisi E; Bora G; Asteggiano E; Olivetti S; Lausi P; Ardissone F; Oliaro A
Eur J Cardiothorac Surg; 2015 Jun; 47(6):1037-43. PubMed ID: 25391390
[TBL] [Abstract][Full Text] [Related]
29. Treatment options in stage III non-small cell lung cancer.
Paraschiv B; Diaconu CC; Dumitrache-Rujinski S; Belaconi IN; Constantinescu T; Stroescu CC; Dantes E; Fildan AP; Bogdan MA; Toma CL
Pneumologia; 2016; 65(2):67-70. PubMed ID: 29538961
[TBL] [Abstract][Full Text] [Related]
30. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition).
Socinski MA; Crowell R; Hensing TE; Langer CJ; Lilenbaum R; Sandler AB; Morris D;
Chest; 2007 Sep; 132(3 Suppl):277S-289S. PubMed ID: 17873174
[TBL] [Abstract][Full Text] [Related]
31. Cancer patients' attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision support.
Brundage MD; Feldman-Stewart D; Cosby R; Gregg R; Dixon P; Youssef Y; Mackillop WJ
Patient Educ Couns; 2001 Nov; 45(2):149-57. PubMed ID: 11687329
[TBL] [Abstract][Full Text] [Related]
32. Survival Implications of De Novo Versus Recurrent Metastatic Non-Small Cell Lung Cancer.
Moore S; Leung B; Wu J; Ho C
Am J Clin Oncol; 2019 Mar; 42(3):292-297. PubMed ID: 30608237
[TBL] [Abstract][Full Text] [Related]
33. An overview of mortality & predictors of small-cell and non-small cell lung cancer among Saudi patients.
Alghamdi HI; Alshehri AF; Farhat GN
J Epidemiol Glob Health; 2018 Mar; 7 Suppl 1(Suppl 1):S1-S6. PubMed ID: 29801587
[TBL] [Abstract][Full Text] [Related]
34. A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer.
Or M; Liu B; Lam J; Vinod S; Xuan W; Yeghiaian-Alvandi R; Hau E
Sci Rep; 2021 Mar; 11(1):5939. PubMed ID: 33723301
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care.
Temel JS; Greer JA; Admane S; Gallagher ER; Jackson VA; Lynch TJ; Lennes IT; Dahlin CM; Pirl WF
J Clin Oncol; 2011 Jun; 29(17):2319-26. PubMed ID: 21555700
[TBL] [Abstract][Full Text] [Related]
36. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
37. [Treatment and prognosis of advanced stage non-small-cell lung cancer].
Chermiti Ben Abdallah F; Ben Ali G; Sadok Boudaya M; Mlika M; Chtourou A; Taktak S; Ben Kheder A
Rev Mal Respir; 2014 Mar; 31(3):214-20. PubMed ID: 24680112
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of patient-reported outcome measures (PROMs) in adults with non-small cell Lung Cancer: a scoping review.
Liao K; Wang T; Coomber-Moore J; Wong DC; Gomes F; Faivre-Finn C; Sperrin M; Yorke J; van der Veer SN
BMC Cancer; 2022 Oct; 22(1):1076. PubMed ID: 36261794
[TBL] [Abstract][Full Text] [Related]
39. The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer.
Abu-Hejleh T; Chrischilles EA; Halfdanarson TR; Simon C; Pendergast JF; Jiang D; Smith CJ; Porter AT; Carter KD; Wallace RB;
Am J Clin Oncol; 2016 Apr; 39(2):126-31. PubMed ID: 24632817
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Value of Expression of MicroRNAs in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Zhan B; Lu D; Luo P; Wang B
Clin Lab; 2016 Nov; 62(11):2203-2211. PubMed ID: 28164670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
